- Trials with a EudraCT protocol (87)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
87 result(s) found for: Chronic total occlusion.
Displaying page 1 of 5.
EudraCT Number: 2013-000915-26 | Sponsor Protocol Number: CMMo-OCC-2012 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and v... | |||||||||||||
Medical condition: Chronic coronary occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001452-42 | Sponsor Protocol Number: HCB.2021.1309 | Start Date*: 2023-01-12 |
Sponsor Name:HOSPITAL CLINIC BARCELONA | ||
Full Title: EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE | ||
Medical condition: Coronary artery chronic total occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004392-23 | Sponsor Protocol Number: T189/2016 | Start Date*: 2018-02-08 |
Sponsor Name:Turku University Hospital | ||
Full Title: 68Ga-NODAGA-RGD cardiac PET in patients with acute myocardial infarction or chronic total coronary occlusion | ||
Medical condition: Acute or chronic coronary artery occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002675-17 | Sponsor Protocol Number: TIGER-BVS | Start Date*: 2014-05-30 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization | ||
Medical condition: Chronic total coronary occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003696-30 | Sponsor Protocol Number: 201928 | Start Date*: 2016-03-11 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 we... | ||||||||||||||||||
Medical condition: COPD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005212-14 | Sponsor Protocol Number: 200812 | Start Date*: 2016-04-20 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary diseas... | |||||||||||||
Medical condition: in subjects with chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) RO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005444-33 | Sponsor Protocol Number: D6571C00001 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 24 week treatment, multicenter, randomized, double blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 μg/formoterol fumarate 12 μg ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003104-39 | Sponsor Protocol Number: SIS-05-2013 | Start Date*: 2013-12-18 |
Sponsor Name:Fakultní nemocnice Ostrava,Czech republic | ||
Full Title: Randomised Clinical Study of Safety of Efficacy of Extracelular Matrix and Autologous Platelet Rich Plasma Concentrate for Wound Healing (Leg Ulcers Biodesign Wound Healing – LEGEND(A) Study) In... | ||
Medical condition: Chronical ischemic and venous ulcers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004649-28 | Sponsor Protocol Number: CTO-201 | Start Date*: 2015-10-09 |
Sponsor Name:Matrizyme Pharma Corporation | ||
Full Title: A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Pla... | ||
Medical condition: The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularization | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004450-15 | Sponsor Protocol Number: RPL554-CO-202 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Verona Pharma plc | |||||||||||||
Full Title: A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002464-31 | Sponsor Protocol Number: KRT-232-111 | Start Date*: 2021-02-12 | |||||||||||||||||||||
Sponsor Name:Kartos Therapeutics Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/R... | |||||||||||||||||||||||
Medical condition: - Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL) - R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhib... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003206-41 | Sponsor Protocol Number: LOXO-BTK-20030(J2N-OX-JZNU) | Start Date*: 2022-08-03 | |||||||||||
Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) CZ (Trial now transitioned) PT (Prematurely Ended) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000880-34 | Sponsor Protocol Number: 207489 | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000110-15 | Sponsor Protocol Number: SX-CVD3001/2020 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:Alfasigma S.p.A. | |||||||||||||
Full Title: Multicentre, multinational, randomised, double blind, placebo-controlled study on Sulodexide for the management of leg symptoms in patients with chronic venous disease - VEINS (VEnous INvestigation... | |||||||||||||
Medical condition: Chronic Venous Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000074-19 | Sponsor Protocol Number: GCP#03.01.020 | Start Date*: 2014-10-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | |||||||||||||||||||||||||||||||||
Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic... | |||||||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) IT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000188-38 | Sponsor Protocol Number: BUS-P3-02 | Start Date*: 2023-02-21 | |||||||||||
Sponsor Name:Bellus Health, Inc. | |||||||||||||
Full Title: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough In... | |||||||||||||
Medical condition: Refractory or Unexplained Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) SK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002311-64 | Sponsor Protocol Number: SuloPrima | Start Date*: 2021-10-01 | |||||||||||
Sponsor Name:ALFASIGMA CZECH s.r.o. | |||||||||||||
Full Title: Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial | |||||||||||||
Medical condition: Chronic primary venous disease of the lower limbs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003340-24 | Sponsor Protocol Number: LOXO-BTK-18001 | Start Date*: 2019-08-09 | |||||||||||||||||||||
Sponsor Name:Loxo Oncology, Inc. | |||||||||||||||||||||||
Full Title: A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000238-16 | Sponsor Protocol Number: APD791-202 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane... | |||||||||||||
Medical condition: Microvascular Obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000223-20 | Sponsor Protocol Number: BUS-P3-01 | Start Date*: 2023-02-01 | |||||||||||
Sponsor Name:Bellus Health, Inc. | |||||||||||||
Full Title: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, I... | |||||||||||||
Medical condition: Refractory or Unexplained Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
